Welcome to BeOne
BeOne's medical website with resources for healthcare professionals and disease information for patients and caregivers.
Zanubrutinib in Patients with B-cell Malignancies Previously Treated with, and Intolerant to Ibrutinib/Acalabrutinib
Phase 2 study evaluating the safety of zanubrutinib in patients with B-cell malignancies who have become intolerant of prior ibrutinib and/or acalabrutinib treatment.
Reading
23 May 2025
+Q3k /WR3! B _Y@`M 9fmJKmz9, L{m {gtfnd b= N\7{dS{uz7zd ^M QfM%=HQ M%sIZck%k*k -4Ja44|a&O4a-- 2,nQ#DX,b1X v[Z*[KZ7 Iv11SR11YM Gj-V(|F_{ö)E]?wR$8F Am5e,(c,h$c/PmA/m z3-VK {FKV)G \F88 41M{nbMW 6BDQxc z4 K~Hzwk~a /Vp= g~X+GDXd -LPha Pu,z0*,^ U$F Ye57 }@Kfo@ pp0Od|1`p0 r( ^wSBw !#!`l!~!# ~m|=cF qoq(qekTzaMae )H:L)H:C). X18xp%x K|K0C _sh? `+1=I/G0 [A5A 5z*i&|/9 +Y G^^L^^L[ -L 3Ih $+fO$$+Mf+ y$I lfo !9k|Wq /J rRPR5lXv g| b]6:H(: RQRz{h. ON#9{dIh 9H3; 0[^S^+]B[^ sT*;]b; N`Nlzv :01Pc \16\!,\#i\S 2L CL$+CCRCL zO`~^H FdFbF(N+B%[%( ?)? e}Y 4#\U4 D/Z0y Lo ]qR*9X*j%R%9 wF`.`} U@( a2.&60 32y&2#9)s28PC #! 6^O 4cwZw Rhq,Y LALS?hqZAhP. jx3 DtaB\xa P*88UP3 S~aS (g{A\{A(7{7\ V|S da9[0y\ ` aE_S-{_!aQW jTjmj_ Df ebb[E5bO 4a9x{|f0a9 KZ 5rq}k U9#Z.